|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma显示文摘 | Bracko M US-Krasovec M Cufer T | 2001 | Anal Quant Cytol Histol2001，23，1： | 1 |
| 2 | Proteases and metastasis: clinical relevance nowadays? 显示文摘 | Decock J Paridaens R Cufer T | 2005 | Curr Opin Oncol2005，17，1： | 1 |
| 3 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib(IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ) non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticaneer Drugs2006，17，4： | 1 |
| 4 | Prognostic factors in inva- sive bladder carcinoma treated by combined modality protocol ( or- gansparing approach) 显示文摘 | Matos T Cufer T Cervek J | 2000 | Int J Radiation Oncology Biol Phys2000，46，2： | 1 |
| 5 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲ b or Ⅳ) non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 6 | Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as firstline chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase Ⅲ Trial显示文摘 | Biganzoli L Cufer T Bruning P | 2002 | J Clin Oncol2002，20，14： | 1 |
| 7 | Prognostic and predictive value of the urokinase-type plasminogen activator and its inhibitors PAI-1 and PAI-2 in operable breast cancer显示文摘 | Cufer T Borstnar S Vrhovec I | 2003 | Int-J-Biol-Markers2003，18，2： | 1 |
| 8 | Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer显示文摘 | Cufer T Cemazau M | 2004 | Anti cancer Drugs2004，15，6： | 1 |
| 9 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ)non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 10 | Update on systemic therapy of advanced non - small - cell lung cancer 显示文摘 | Cufer T Knez L | 2014 | Expert Rev Anticancer Ther2014，14，10： | 1 |
| 11 | PhaseⅡ,open-label,randomized study(SIGN)of single-agent gefitinib(IRESSA)or docetaxel as second-line therapy in patients with advanced(stageⅢb orⅣ)non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anti-Cancer Drug2006，17，4： | 1 |
| 12 | Prognositc significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma显示文摘 | BRACKO M US-KRASOVEC M CUFER T | 2001 | Anal Quant Cytol Histol2001，23，1： | 1 |
| 13 | Results from a Phase II, Open-label, Randomized Study (SIGN)Comparing Gefitinib with Docetaxel as Second-line Therapy in Patients with Advanced( Stage IIlb or IV)Non-small Cell Lung Cancer显示文摘 | Cufer T Vrdoljak E | 2005 | Proc Am Soc Clin Oncol2005，23，16： | 1 |
| 14 | Phase II, open-label,randomized study( SIGN ) of singleagent gefitinib( IRESSA ) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer 显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 15 | Phase II, open label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second line therapy in patients with advanced ( stage IIIb or IV)non -small -cell lung cancer 显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 16 | Adjuvant endocrine therapy for perimenopausal women with early breast cancer 显示文摘 | Ortmann O Cufer T Dixon JM | 2009 | Breast2009，18，1： | 1 |
| 17 | Phase Ⅱ, open-label, randomized study(SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ) non-small-cell lung cancer 显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anti-Cancer Drugs2006，17，4： | 1 |
| 18 | Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial显示文摘 | BIGANZOLI L CUFER T BRUNING P | 2002 | J Clin Oncol2002，20，14： | 1 |
| 19 | Phase 11 , open - label, ran- domized study(SIGN) of single - agent gefitinib(IRESSA) or do- cetaxel as second - line therapy in patients with advanced ( stage Ill b or IV ) non - small - cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 20 | The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tarnoxifen monotherapy: an immunohistochemical study显示文摘 | GOLOUH R CUFER T SADIKOV A | 2008 | Breast Cancer Res Trent2008，110，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员